Memorial Sloan Kettering Cancer Center is starting a new clinical trial of MCARH109 and MCARH125 in People With Multiple Myeloma.
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
The clinical trial started in June 20, 2022 and will continue throughout June 20, 2024.
Maximum tolerated dose/MTS of MCARH109 and MCARH125 T cells will be primary outcome measure. To determine maximum tolerated dose (MTD) of MCARH109 and MCARH125 T cells in patients with refractory, persistent, or progressive MM.